Response to reslizumab in a real-life setting: biologic-naïve asthma patients versus switchers.
L. Pérez De Llano (Lugo, Spain), B. Cosío (Palma de Mallorca, Spain), I. Lobato Astiárraga (Valladolid, Spain), G. Soto Campos (Jerez, Spain), M. Alonso Tejedor (Alcorcón, Spain), N. Marina Malanda (Barakaldo, Spain), A. Padilla Galo (Marbella, Spain), I. Urrutia Landa (Galdakao, Spain), J. Michel De La Rosa (San Sebastián, Spain), I. García Moguel (MAdrid, Spain)
Source: International Congress 2022 – Studies targeting IL-5 pathways in asthma
Session: Studies targeting IL-5 pathways in asthma
Session type: Thematic Poster
Number: 2140
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Pérez De Llano (Lugo, Spain), B. Cosío (Palma de Mallorca, Spain), I. Lobato Astiárraga (Valladolid, Spain), G. Soto Campos (Jerez, Spain), M. Alonso Tejedor (Alcorcón, Spain), N. Marina Malanda (Barakaldo, Spain), A. Padilla Galo (Marbella, Spain), I. Urrutia Landa (Galdakao, Spain), J. Michel De La Rosa (San Sebastián, Spain), I. García Moguel (MAdrid, Spain). Response to reslizumab in a real-life setting: biologic-naïve asthma patients versus switchers.. 2140
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|